Data Quality
Data Quality
Beyond Imaging: The Transformation to Data Quality
Building on more than 40 years of leadership in medical image enhancement, ContextVision is advancing its legacy through the transformation to Data Quality— a focused ultrasound program that leverages AI-powered image-enhancements to enable organ and disease specific quantitative imaging solutions to point-of-care ultrasound.
The goal is to deliver a more rapid and accurate detection as well as staging of chronic conditions, such as MASLD (Metabolic dysfunction-associated steatotic liver disease). By combining organ-specific image enhancement, user-independent workflows, as well as quantitative disease-specific digital biomarkers, the platform is being built to support near-patient diagnostic solutions.
Why Data Quality matters?
Chronic diseases like MASLD affect more than 25% of the global population. Traditional patient journeys are dependent on multiple clinical specialists, diagnostic technologies, and care settings, which results in a diagnostic pathway that is costly and hard to scale. That’s why ContextVision is developing solutions designed to simplify patient journeys by facilitating a timely diagnostic and treatment decision— directly at the point of care.
Innovating for our Customers
The Data Quality Initiative builds on our proven Image Quality expertise and is being developed as a modular add-on. Its architecture is intended to let OEM partners explore organ- and disease specific feature enhancements as well as quantitative solutions for digital biomarkers in their ultrasound systems with or without workflow adjustments.
By targeting standardized outputs and user-independent interpretation, the program aims to reduce variability and support more consistent diagnostics across product lines. The goal is to give OEMs the freedom to customize now and the headroom to scale later—advantages that matter in a fast-moving near-patient imaging market.
Further reading:
Press Release – Organ-specific Data Quality launch (18 July 2024)
Press Release – UW, Waterloo & InPhase partnerships (8 April 2025)
ContextVision 1st Target is Liver Diagnostics
In late 2024, the Data Quality project reached a major milestone: a formal partnership with the University of Washington focused on developing digital biomarkers for early detection and monitoring of liver disease. To accelerate progress, ContextVision has also onboarded the University of Waterloo and InPhase Solutions AS, adding specialized ultrasound and quantitative imaging expertise to the team. And this is only the beginning – we look forward to announcing more partnerships soon.
Beyond Imaging: The Transformation to Data Quality
Building on more than 40 years of leadership in medical image enhancement, ContextVision is advancing its legacy through the transformation to Data Quality— a focused ultrasound program that leverages AI-powered image-enhancements to enable organ and disease specific quantitative imaging solutions to point-of-care ultrasound.
The goal is to deliver a more rapid and accurate detection as well as staging of chronic conditions, such as MASLD (Metabolic dysfunction-associated steatotic liver disease). By combining organ-specific image enhancement, user-independent workflows, as well as quantitative disease-specific digital biomarkers, the platform is being built to support near-patient diagnostic solutions.
Why Data Quality matters?
Chronic diseases like MASLD affect more than 25% of the global population. Traditional patient journeys are dependent on multiple clinical specialists, diagnostic technologies, and care settings, which results in a diagnostic pathway that is costly and hard to scale. That’s why ContextVision is developing solutions designed to simplify patient journeys by facilitating a timely diagnostic and treatment decision— directly at the point of care.
Innovating for our Customers
The Data Quality Initiative builds on our proven Image Quality expertise and is being developed as a modular add-on. Its architecture is intended to let OEM partners explore organ- and disease specific feature enhancements as well as quantitative solutions for digital biomarkers in their ultrasound systems with or without workflow adjustments.
By targeting standardized outputs and user-independent interpretation, the program aims to reduce variability and support more consistent diagnostics across product lines. The goal is to give OEMs the freedom to customize now and the headroom to scale later—advantages that matter in a fast-moving near-patient imaging market.
Further reading:
Press Release – Organ-specific Data Quality launch (18 July 2024)
Press Release – UW, Waterloo & InPhase partnerships (8 April 2025)
ContextVision 1st Target is Liver Diagnostics
In late 2024, the Data Quality project reached a major milestone: a formal partnership with the University of Washington focused on developing digital biomarkers for early detection and monitoring of liver disease. To accelerate progress, ContextVision has also onboarded the University of Waterloo and InPhase Solutions AS, adding specialized ultrasound and quantitative imaging expertise to the team. And this is only the beginning – we look forward to announcing more partnerships soon.